The investigators seek to derive and validate a clinically useful risk score for patients with Coronavirus Disease 2019 to aide clinicians in the safe discharge of patients.
The investigators a-priori plan the following analysis:
1. Derivation and Retrospective Validation.
- Select all adult patients with a positive reverse transcription polymerase chain
reaction for severe acute respiratory syndrome coronavirus 2 beginning March 1,
2020 until approximately 1000 patients are included.
- Use 75% of this cohort to develop a simple risk-score that prognosticates a
patient's suitability for discharge (no supplemental oxygen, no intensive care
unit, and no death). Use multivariable logistic regression with forward selection
informed by clinical judgement to choose variables a priori that emphasizes readily
available data and easy calculation for use at the point of care.
- Use 25% of this cohort to retrospectively validate the risk-score.
2. Prospective Validation.
- Select all adult patients with a positive reverse transcription polymerase chain
reaction for severe acute respiratory syndrome coronavirus 2 as soon as the
derivation cohort in step 1 is assembled. Include approximately 250 patients.
- Use this sample to prospectively validate the risk-score developed in part 1.
Inclusion Criteria:
- Positive reverse transcription polymerase chain reaction for severe acute respiratory
syndrome coronavirus 2
- Age 18 and older
Exclusion Criteria:
- None
Brigham and Women's Hospital
Boston, Massachusetts, United States